Bogle Investment Management’s Teva Pharmaceuticals TEVA Stock Holding History

Bogle Investment Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-868,375	Closed	-$7.8M	–	416
2020 Q1	$7.8M	Buy	868,375 +532,095	+158%	+$5.45M	0.82%	54
2019 Q4	$3.3M	Hold	336,280	–	–	0.31%	106
2019 Q3	$2.31M	Buy	336,280 +243,152	+261%	+$1.86M	0.2%	125
2019 Q2	$860K	Buy	+93,128	New	+$1.12M	0.07%	215
2015 Q4	–	Sell	-220,736	Closed	-$12.5M	–	441
2015 Q3	$12.5M	Buy	220,736 +100	+0%	+$6.48K	0.88%	13
2015 Q2	$13M	Sell	220,636 -442	-0.2%	-$27.3K	0.97%	11
2015 Q1	$13.8M	Hold	221,078	–	–	0.95%	20
2014 Q4	$12.7M	Buy	221,078 +7,200	+3%	+$401K	0.84%	24
2014 Q3	$11.5M	Buy	213,878 +10,100	+5%	+$535K	0.75%	51
2014 Q2	$10.7M	Buy	203,778 +128,200	+170%	+$6.55M	0.72%	57
2014 Q1	$3.99M	Buy	+75,578	New	+$3.49M	0.27%	119

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bogle Investment Management's TEVA Position: Q2 2020 in Review

Bogle Investment Management sold out of Teva Pharmaceuticals (TEVA) in Q2 2020, closing a stake of 868,375 shares — an estimated $7.8M sold.

Bogle Investment Management first reported a position in TEVA in Q1 2014 and held it in 11 quarters. The position peaked at $13.8M in Q1 2015. 455 funds tracked by Wall St. Rank hold TEVA as of Q2 2020.

Bogle Investment Management reported no remaining Teva Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
Bogle Investment Management sold 868,375 Teva Pharmaceuticals shares in Q2 2020, an estimated $7.8M.
Bogle Investment Management first reported a position in Teva Pharmaceuticals in Q1 2014 and held it in 11 quarters.
Bogle Investment Management's Teva Pharmaceuticals position peaked at $13.8M in Q1 2015.
455 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2020.

Based on Bogle Investment Management's 13F filing for Q2 2020, filed 13 Aug 2020.